AllSci News
Brenig Launches First-in-Human Trial of Brain-Selective NLRP3 Inhibitor BT-409
Brenig Therapeutics has initiated the first clinical evaluation of BT-409, a brain-selective small molecule designed to inhibit the NLRP3 inflammasome in neurodegenerative…
Kinaset Therapeutics Raises $103 Million Series B to Advance Inhaled Asthma Drug Therapy
Kinaset Therapeutics Secures USD 103 Million to Advance Inhaled Asthma Therapy Boston-based Kinaset ...
Mediar Therapeutics Raises $76 Million in Series B to Advance Anti-Fibrotic Drug Pipeline
Mediar Therapeutics Secures USD 76 Million to Advance Anti-Fibrotic Pipeline Boston-based Mediar The...
GVV858 Phase 1 Trial: Targeting CCNE1-Amplified Advanced Solid Tumors in Breast and Prostate Cancer
Novel Cancer Therapy GVV858 Enters First-in-Human Trial Targeting Advanced Solid Tumors A first-in-...
J&J’s Tecvayli beats standard of care in early-relapse MM
Johnson & Johnson announced positive Phase 3 data showing that Tecvayli (teclistamab-cqyv) monotherapy significantly improved progression-free survival (PFS) and overall survival (OS)…
DPTX3186 Phase 1 Trial Targets Wnt Pathway in Advanced Solid Tumor Treatment
Novel Wnt Pathway Inhibitor Enters First-in-Human Trial for Solid Tumors Researchers have initiated a first...
Innovent Biologics' IBI3003 Enters First-in-Human Phase I/II Trial for Multiple Myeloma
Novel Multiple Myeloma Therapy Enters First-in-Human Trial Innovent Biologics has initiated a first...
Caldera Launches with USD 112.5m Series A, Puts IL-23p19 / TL1A BsAb into Phase 1
US-based biotech Caldera Therapeutics announced its launch with the finalization of a USD 112.5 million Series A funding round, set to focus…
AstraZeneca’s AZD9750 PROTAC Enters Trials for Metastatic Prostate Cancer
AstraZeneca is initiating a first-in-human clinical trial of AZD9750, a novel androgen receptor (AR) proteolysis targeting chimera (PROTAC), targeting patients with metastatic…
FDA Approves Sentynl’s Zycubo for Rare Genetic Copper Transport Disorder
The US FDA has approved Zycubo (copper histidinate), a novel subcutaneous injectable therapy developed by Sentynl Therapeutics, for treating Menkes disease in…
Boehringer Ingelheim Puts First-in-Class IL-11 Inhibitor to Phase 2 Test in IPF
Boehringer Ingelheim announced the initiation of a Phase 2a clinical trial for BI 765423, a novel monoclonal antibody targeting interleukin-11 (IL-11), in…
Shanghai Mental Health Center Launches First-in-Human Trial of Innovative SP-101 NMDA Antagonist
Researchers at Shanghai Mental Health Center have initiated a first-in-human clinical trial of SP-101, a novel intravenous non-competitive NMDA receptor antagonist designed to potentially address neuropsychiatric conditions.
FDA Approval
FDA Approves First Therapy for Rare Genetic Copper Transport Disorder The U.S. Food and Drug Adminis...
Pierre Fabre’s T-cell therapy tabelecleucel met with second FDA CRL
Pierre Fabre Pharmaceuticals revealed that a Biologic License Application (BLA) for Epstein-Barr virus (EBV) T-cell therapy tabelecleucel has been met with a…
AbbVie enters PD-1/VEGF BsAb field via RemeGen licensing deal
AbbVie (NYSE: ABBV) announced the signing of an exclusive licensing agreement with China-based RemeGen to develop, manufacture, and commercialize RC148, a novel…
The AllSci Brief
Systematic R&D and deal news. Daily.